Visiting/Using the site requires accepting our privacy policies - Click to accept

Precision Nanomedicine

The official journal of CLINAM

About the Journal: Precision Nanomedicine (PRNANO) is a peer-reviewed, not-for-profit, international society journal to promote all practical, rational, and progressive aspects of theory and practice of nanomedicine, from basic research through translational and clinical aspects including commercialization.

PRNANO provides an open access forum with reliable content and quick turnaround time.

We invite authors to submit both original, as well as replication studies. Discussions of negative results are also welcome if they move the field forward.  Papers are published continuously then organized into quarterly issues.

Please, note that HTML files are optimized for computer scans and pdf files for download and reading.

PRNANO is digitally distributed by a scientists-owned non-profit publisher: Andover House Inc, 138 River Rd, Andover, Massachusetts, 01810, USA.

 ISSN: 2639-9431 (online)

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
- Krausz AE, Adler BL, Makdisi J, Schairer D, Rosen J, Landriscina A, Navati M, Alfieri A, Friedman JM, Nosanchuk JD, Rodriguez-Gabin A, Ye KQ, McDaid HM, Friedman AJ.
Liposomal formulation of polyacrylate-peptide conjugate as a new vaccine candidate against cervical cancer
- Khongkow M, Liu TY, Bartlett S, Hussein WM, Nevagi R, Jia ZF, Monteiro MJ, Wells J, Ruktanonchai UR, Skwarczynski M, Toth I.
Specific Molecular Recognition as a Strategy to Delineate Tumor Margin Using Topically Applied Fluorescence Embedded Nanoparticles
- Barton S, Li B, Siuta M, Janve VA, Song J, Holt CM, Tomono T, Ukawa M, Kumagai H, Tobita E, Wilson K, Sakuma S, Pham W.
Download PDF Views: 359     Downloads: 55

Table of Content

Precision Nanomedicine, 2018 April; Vol. 1, Issue 1

(Click here to download hi-res version of the cover page)


The Story of Precision Nanomedicine – the Journal

Lajos P Balogh

Editor-in-Chief, Precision Nanomedicine

Prec. Nanomed. 2018, Apr; 1(1):1-4. DOI: 10.29016/180328.1

There is a growing need for responsible publishing and sharing reliable results. This means not just publishing for the sake of having one more publication, but sharing information which, in addition to basic science, educates about research and development (R&D) knowledge, and how to turn knowledge into practice. Forced to chase originality and novelty, many investigators now pursue only novel materials and complicated approaches to fulfill the criteria to make their manuscripts acceptable. Originality and novelty are like designs and prototypes at a fashion show: they reveal a new concept but most of them could not be worn on the streets. Without in-depth and reproducible studies and R&D knowledge, it is impossible to develop practical (nano)medicines for everyday use. While many societies hire for-profit publishers to run their media, we have decided to create our own publishing company. In January 2018, and with the support of the European Foundation for Clinical Nanomedicine (CLINAM) and the International Society for Nanomedicine (Basel, Switzerland) we founded our own publishing organization in New England – in one of the traditional hubs for medicine and materials science.


Balancing Interests of Science, Scientists, and the Publishing Business

Lajos P Balogh

Editor-in-Chief, Precision Nanomedicine

Prec. Nanomed. 2018 Apr; 1(1):5-14. DOI:10.29016/180418.1

In the closely coupled system of diverse interests of science, those of scientists (authors, reviewers, and readers), and their organizations (universities, research institutions, and publishers) every component is undergoing major changes in the digital era. In reality, these interests are deeply interconnected and long-term dominance of any one of these could hinder progress in many different ways. For science, originality and novelty do not have merit without reproducibility; for scientists, quantity is not a substitute for quality, and if businesses focus only on profit, it will suppress the value of their publications. Science, scientists, and organizations not only coexist, but cannot exist without each other, therefore all participants must adjust their actions to avoid devaluation of the whole. Many efforts are underway to regain this balance, and one possible approach – ours at Precision Nanomedicine – is described here.


Improving Innovation in Nano-Healthcare Funding

Mike Eaton


Prec. Nanomed. 2018 Apr;1(1):15-17 DOI:10.29016/180108.1

“…the transition from research to development requires informed debate and high-quality data and is a very challenging milestone. Researchers often say they are developing a new drug, when they are in fact doing research – funders also use the terms (R or D) interchangeably - an unfortunate consequence of their academic training. A simple test is if you don’t know actually what you are developing - you are in research.”

From the Clinical Editor: The author here describes the importance of R&D knowledge and its necessary funding. This is often a neglected aspect by many researchers and funding agencies, as the ultimate aim of carrying out research is creating products to bring benefits to clinical patients.


Origins to Outcomes: A Role for Extracellular Vesicles in Precision Medicine

John Savage a,b,, Ciaran Manus Maguire b,c, Adriele Prina-Mello b,c

aSchool of Medicine, Trinity College Dublin, Dublin 2, Ireland.

bLaboratory for Biological Characterization of Advanced Materials (LBCAM), Department of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, Dublin, Dublin 8, Ireland.

cAMBER Centre, CRANN Institute, Trinity College Dublin, Dublin 2, Ireland.

Prec. Nanomed. 2018, Apr; 1(1):18-42. DOI: 10.29016/180419.1

Extracellular vesicles (EVs) are of great interest in biological research, and though they are a relatively recent discovery, they have rapidly shown great potential for use in clinical applications. The various techniques used in EV isolation along with their respective strengths, weaknesses, and potential for downstream applications are outlined here. A brief description of the different approaches in exosome characterisation are subsequently described. It has been highlighted that despite the recent developments in these processes, there is still a great deal of refinement to be made. EVs are produced by almost all cell types, found in many biological samples, and are implicated in multiple biological processes including cargo trafficking, cell-cell communication, and signal transduction. The presence of these EVs and their varied cargo in a biological sample can be indicative in disease diagnosis, and guide precision medicine-based approaches to disease management. EVs have been reported to act in the benefit of the cell through moderating repair and regeneration, but they can also act to the detriment of the cell through increased tumorigenesis and metastasis. This duality is intriguing as it can allow for the use of EVs in distinct therapeutic approaches and displays their versatility in potential downstream applications. In this review, examples of the cellular roles of EVs and their applications in pathological and regenerative contexts are explored. In reviewing some of the developments made in recent times, EVs are shown to be very promising both in diagnostic and therapeutic approaches.

From the Clinical Editor: Extracellular vesicles (EVs) are involved in various biological processes such as cargo trafficking, cell-cell communication, and signal transduction. The advances in nanotechnology have enabled researchers to utilize EVs for potential use in clinical applications, within the so-called precision medicine approach. In this review article, the authors discuss the techniques used in EV isolation in length, together with their applications in clinical diagnosis and therapeutics.

A porcine model of complement activation-related pseudoallergy to nano-pharmaceuticals: Pros and cons of translation to a preclinical safety test

János Szebeni1,2,5, Péter Bedőcs3,4, László Dézsi1,2 , Rudolf Urbanics1,2

1Nanomedicine Research and Education Center, Dept. of Pathophysiology, Semmelweis University, Budapest, Hungary

2SeroScience Ltd., Budapest, Hungary

3Uniformed Services University of the Health Sciences, Bethesda, MD, USA

4Henry M Jackson Foundation, Bethesda, MD, USA

5Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, Miskolc University, Miskolc, HungaryPrec. Nanomed. 2018 Apr;1(1):63-75, DOI: 10.29016/180427.1